|
1
|
Smith C, Novara ME, Cona A, Dolcimascolo A, Cancellieri G, Mortillaro F, Giannini EO, Carollo A, Mularoni A, Provenzani A. Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review. Pharmaceuticals (Basel) 2024; 17:765. [PMID: 38931432 PMCID: PMC11206602 DOI: 10.3390/ph17060765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2024] [Revised: 05/25/2024] [Accepted: 06/06/2024] [Indexed: 06/28/2024] Open
Abstract
The SARS-CoV-2 infection has been associated with important mortality, particularly in immunocompromised patients, including solid organ transplant (SOT) recipients. Remdesivir (RDV) is an antiviral drug that has proven to be effective in reducing the replication of the virus in host cells, by which it may reduce the progression of symptoms and, consequently, the length of hospital stay and mortality. Randomized controlled trials have evaluated its use in the general population but never in SOT recipients. For the first time in this review, the safety and efficacy of RDV is evaluated in this specific population. The literature research was conducted using PubMed/MEDLINE and Scopus databases from 1 January 2020 to 24 November 2023, and 23 studies were analyzed. Although no clinical studies specifically evaluating this population have been conducted yet, RDV is likely safe for SOT patients when compared to the general population, so prescribers should consider utilizing RDV in SOT patients who are at high risk for progression to severe COVID-19. Future research will allow for the confirmation of the observed results and the acquisition of broader and clearer data regarding the safety and efficacy of the drug in this specific setting.
Collapse
Affiliation(s)
- Catherine Smith
- School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 5261, USA;
| | - Maria Eugenia Novara
- Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy; (A.C.); (A.P.)
| | - Andrea Cona
- Infectious Diseases Unit, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy; (A.C.); (A.M.)
| | - Anna Dolcimascolo
- School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy; (A.D.); (G.C.); (F.M.); (E.O.G.)
| | - Giulia Cancellieri
- School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy; (A.D.); (G.C.); (F.M.); (E.O.G.)
| | - Francesca Mortillaro
- School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy; (A.D.); (G.C.); (F.M.); (E.O.G.)
| | - Enrico Ottavio Giannini
- School of Specialization in Hospital Pharmacy, University of Palermo, 90133 Palermo, Italy; (A.D.); (G.C.); (F.M.); (E.O.G.)
| | - Anna Carollo
- Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy; (A.C.); (A.P.)
| | - Alessandra Mularoni
- Infectious Diseases Unit, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy; (A.C.); (A.M.)
| | - Alessio Provenzani
- Clinical Pharmacy Service, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT), 90127 Palermo, Italy; (A.C.); (A.P.)
| |
Collapse
|
|
2
|
Lu J, Butler-Wu SM. Home and Clinical Laboratory Improvement Amendments-Waived Testing for Infectious Diseases-How Do These Fit in the Testing Landscape? Clin Lab Med 2024; 44:13-21. [PMID: 38280794 DOI: 10.1016/j.cll.2023.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2024]
Abstract
Though testing for infectious diseases has long been performed in traditional clincial laboratory settings, more widespread availability of waived testing is expanding accessibility of patients to rapid test results. This is being further expanded to home testing. Nevertheless, with this greater democratization and availability of clinical testing there are important limitations that need to be balanced. In this article, we review the current test landscape for infectious diseases waived testing and opportunities for assuring optimal quality testing.
Collapse
Affiliation(s)
- Jacky Lu
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
| | - Susan M Butler-Wu
- Department of Pathology, Keck School of Medicine of the University of Southern California, HMR 211, 2011 Zonal Avenue, Los Angeles, CA 90033, USA.
| |
Collapse
|